salicylic acid has been researched along with imiquimod in 46 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 17 (36.96) | 29.6817 |
| 2010's | 24 (52.17) | 24.3611 |
| 2020's | 5 (10.87) | 2.80 |
| Authors | Studies |
|---|---|
| Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M | 1 |
| Housman, TS; Jorizzo, JL | 1 |
| Ali, A; Ransdell, BL; Tucker, SB | 1 |
| Smolinski, KN; Yan, AC | 1 |
| Lio, P | 1 |
| Hibma, M; Leong, CM; Tarbotton, J | 1 |
| Antoniou, C; Katsarou, A; Kontochristopoulos, G; Kouris, A; Lagogiani, I; Stefanaki, C | 1 |
| Alarcon, I; Sibbring, GC; Stockfleth, E | 1 |
| Devi, N; Jain, A; Katare, OP; Sharma, G; Thakur, K | 1 |
| Koning, S; Kruithof, EJ; Sollie, A; van der Sande, R; van der Wouden, JC; van Suijlekom-Smit, LW | 1 |
| Cantor, AS; Hardy, CL | 1 |
| Katare, OP; Raza, K; Sharma, G; Sharma, M; Singh, B | 1 |
| Ciccarese, G; Drago, F; Parodi, A | 1 |
| Ahmed, I; Berth-Jones, J | 1 |
| Martinez, MI; Mihm, MC; North, PE; Sanchez-Carpintero, I | 1 |
| Levine, N; Morrison, L; Salasche, SJ | 1 |
| Binder, B; Cerroni, L; Kerl, H; Richtig, E; Smolle, J; Wolf, IH | 1 |
| Armario-Hita, J; Fernández-Vozmediano, J | 1 |
| Casado, M; González-Beato, M; Mayor, M; Miralles, L; Pizarro, A; Sigüenza, M; Vidaurrázaga, C | 1 |
| Adim, SB; Baskan, EB; Toker, S; Tunali, S; Turan, A | 1 |
| Goh, MS | 1 |
| Bunker, CB; Singh, S | 1 |
| Goldberg, LH; Harting, M; Vujevich, J | 1 |
| Harth, W; Heber, G; Helbig, D; Pönitzsch, I; Simon, JC; Wetzig, T | 1 |
| Fosko, SW; Missall, TA | 1 |
| Beer, KR; Hanke, CW; Levy, S; Rosen, T; Stockfleth, E; Wu, J | 1 |
| Abramovits, W; Berman, B; Kulp, J; Levy, S; Rigel, DS; Swanson, N | 1 |
| Adams, M; Fein, MC; Furst, J; Kulp, J; Levy, S; Meng, TC | 1 |
| Gollnick, HP; Quist, SR | 1 |
| Berman, B; Bruce, S; Hanke, CW; Kulp, J; Levy, S; Swanson, N | 1 |
| Bonnekoh, B; Fehsecke, D; Franke, I; Froster, UG; Gollnick, HP; Helmdach, M; Kraus, C; Quist, SR; Reis, A | 1 |
| Urbina, F | 1 |
| Goldenberg, G; Kaur, M; Smith, CC; Swanson, N | 2 |
| Argenziano, G; Drummond, A; Lallas, A; Longo, C; Moscarella, E; Piana, S; Pichler, J; Zalaudek, I | 1 |
| Alomar, A; Aractingi, S; Dakovic, R; Dirschka, T; Gupta, G; Peris, K; Stockfleth, E | 3 |
| Capizzi, R; Fargnoli, MC; Peris, K; Tambone, S | 1 |
| Bartha, Á; Dirschka, T; Schmitz, L | 1 |
| Grady, BE; Spencer, JM | 1 |
| Balasis, S; Georgiou, S; Koumoundourou, D; Mallioris, AF; Plachouri, KM | 1 |
| Borgia, F; Cannavò, SP; Giuffrida, R | 1 |
| Landucci, G; Savoia, P; Tarantino, V; Veronese, F; Zavattaro, E | 1 |
| Dirschka, T; Gollnick, H; Kerl, H; Kunstfeld, R; Ostendorf, R | 1 |
| Castagnetti, E; Cortelazzi, C; Di Nuzzo, S; Odorici, G; Pellacani, G | 1 |
7 review(s) available for salicylic acid and imiquimod
| Article | Year |
|---|---|
How and when to treat molluscum contagiosum and warts in children.
Topics: Adhesives; Adjuvants, Immunologic; Administration, Topical; Aminoquinolines; Cantharidin; Child; Cimetidine; Cryotherapy; Curettage; Fluorouracil; Hot Temperature; Humans; Imiquimod; Immunotherapy; Irritants; Keratolytic Agents; Laser Therapy; Molluscum Contagiosum; Occlusive Dressings; Pediatrics; Podophyllin; Salicylic Acid; Tretinoin; Warts | 2005 |
Warts, molluscum and things that go bump on the skin: a practical guide.
Topics: Adjuvants, Immunologic; Administration, Topical; Aminoquinolines; Anti-Infective Agents; Cantharidin; Cryotherapy; Diagnosis, Differential; Disease Transmission, Infectious; Humans; Hyperthermia, Induced; Imiquimod; Irritants; Molluscum Contagiosum; Risk Factors; Salicylic Acid; Secondary Prevention; Skin Diseases; Treatment Outcome; Warts | 2007 |
New Topical Treatment Options for Actinic Keratosis: A Systematic Review.
Topics: Administration, Cutaneous; Aminoquinolines; Dermatologic Agents; Diterpenes; Drug Combinations; Facial Dermatoses; Fluorouracil; Humans; Imiquimod; Keratosis, Actinic; Randomized Controlled Trials as Topic; Salicylic Acid; Scalp Dermatoses; Skin; Treatment Outcome | 2016 |
Interventions for cutaneous molluscum contagiosum.
Topics: Adjuvants, Immunologic; Aminoquinolines; Anti-Infective Agents, Local; Benzoyl Peroxide; Cimetidine; Humans; Hydroxides; Imiquimod; Molluscum Contagiosum; Myrtus; Olive Oil; Phytotherapy; Plant Oils; Potassium Compounds; Povidone-Iodine; Randomized Controlled Trials as Topic; Remission, Spontaneous; Salicylic Acid; Sodium Nitrite | 2017 |
[Topical treatment of melanoma skin metastases with imiquimod].
Topics: Administration, Topical; Aged; Aged, 80 and over; Aminoquinolines; Antineoplastic Agents; Head and Neck Neoplasms; Humans; Imiquimod; Male; Melanoma; Scalp; Skin Neoplasms | 2005 |
Imiquimod 3.75% cream (Zyclara) for the treatment of actinic keratoses.
Topics: Adjuvants, Immunologic; Administration, Cutaneous; Aminoquinolines; Combined Modality Therapy; Cryosurgery; Drug Administration Schedule; Face; Humans; Imiquimod; Keratosis, Actinic; Medication Adherence; Scalp | 2011 |
Long-term clinical outcomes of imiquimod 5% cream vs. diclofenac 3% gel for actinic keratosis on the face or scalp: a pooled analysis of two randomized controlled trials.
Topics: Adjuvants, Immunologic; Aged; Anti-Inflammatory Agents, Non-Steroidal; Carcinoma, Squamous Cell; Diclofenac; Facial Neoplasms; Female; Gels; Humans; Imiquimod; Keratosis, Actinic; Male; Middle Aged; Scalp; Skin Cream | 2020 |
11 trial(s) available for salicylic acid and imiquimod
| Article | Year |
|---|---|
Cryotherapy versus imiquimod 5% cream combined with a keratolytic lotion in cutaneous warts in children: A randomized study.
Topics: Aminoquinolines; Child; Child, Preschool; Cryotherapy; Female; Humans; Imiquimod; Keratolytic Agents; Male; Nitrogen; Salicylic Acid; Treatment Outcome; Warts | 2016 |
Cycle therapy of actinic keratoses of the face and scalp with 5% topical imiquimod cream: An open-label trial.
Topics: Adjuvants, Immunologic; Aged; Aminoquinolines; Face; Female; Humans; Imiquimod; Keratosis; Male; Pilot Projects; Scalp; Treatment Outcome | 2002 |
Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: results of two placebo-controlled studies of daily application to the face and balding scalp for two 3-week cycles.
Topics: Adjuvants, Immunologic; Administration, Topical; Adult; Aged; Aged, 80 and over; Aminoquinolines; Dosage Forms; Double-Blind Method; Drug Administration Schedule; Face; Female; Humans; Imiquimod; Keratosis, Actinic; Male; Middle Aged; Scalp; Time Factors | 2010 |
Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: results of two placebo-controlled studies of daily application to the face and balding scalp for two 2-week cycles.
Topics: Adjuvants, Immunologic; Administration, Topical; Adult; Aged; Aged, 80 and over; Aminoquinolines; Dosage Forms; Double-Blind Method; Drug Administration Schedule; Face; Female; Humans; Imiquimod; Keratosis, Actinic; Male; Middle Aged; Scalp; Time Factors | 2010 |
Pharmacokinetics of imiquimod 3.75% cream applied daily for 3 weeks to actinic keratoses on the face and/or balding scalp.
Topics: Aged; Aged, 80 and over; Alopecia; Aminoquinolines; Face; Female; Half-Life; Humans; Imiquimod; Keratosis, Actinic; Male; Middle Aged; Scalp; Skin | 2010 |
Complete clearance is sustained for at least 12 months after treatment of actinic keratoses of the face or balding scalp via daily dosing with imiquimod 3.75% or 2.5% cream.
Topics: Adult; Aminoquinolines; Double-Blind Method; Drug Administration Schedule; Face; Humans; Imiquimod; Keratosis, Actinic; Male; Scalp; Time Factors; Treatment Outcome | 2011 |
Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: two phase 3 multicenter, randomized, double-blind, placebo-controlled studies.
Topics: Adjuvants, Immunologic; Administration, Cutaneous; Aged; Aminoquinolines; Dose-Response Relationship, Drug; Double-Blind Method; Face; Female; Humans; Imiquimod; Keratosis, Actinic; Male; Middle Aged; Scalp; Treatment Outcome | 2013 |
Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: two phase 3, multicenter, randomized, double-blind, placebo-controlled studies.
Topics: Adjuvants, Immunologic; Adult; Aminoquinolines; Dose-Response Relationship, Drug; Double-Blind Method; Face; Female; Humans; Imiquimod; Keratosis, Actinic; Male; Middle Aged; Scalp; Skin Aging; Treatment Outcome | 2014 |
Long-term sustained lesion clearance from Lmax with imiquimod 3.75%, a new field-directed treatment for actinic keratosis.
Topics: Adjuvants, Immunologic; Administration, Topical; Aged; Aminoquinolines; Delayed-Action Preparations; Dose-Response Relationship, Drug; Double-Blind Method; Face; Female; Follow-Up Studies; Humans; Imiquimod; Keratosis, Actinic; Male; Scalp; Severity of Illness Index; Skin; Time Factors; Treatment Outcome | 2015 |
Efficacy of imiquimod 3.75% from Lmax according to the number of actinic keratosis lesions.
Topics: Aged; Aminoquinolines; Antineoplastic Agents; Double-Blind Method; Face; Facial Dermatoses; Female; Humans; Imiquimod; Keratosis, Actinic; Male; Middle Aged; Scalp; Scalp Dermatoses; Severity of Illness Index; Treatment Outcome | 2015 |
Comparative study of imiquimod 3.75% vs. photodynamic therapy for actinic keratosis of the scalp.
Topics: Aminolevulinic Acid; Humans; Imiquimod; Keratosis, Actinic; Male; Photochemotherapy; Photosensitizing Agents; Pilot Projects; Scalp; Treatment Outcome | 2021 |
28 other study(ies) available for salicylic acid and imiquimod
| Article | Year |
|---|---|
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries | 2023 |
Anecdotal reports of 3 cases illustrating a spectrum of resistant common warts treated with cryotherapy followed by topical imiquimod and salicylic acid.
Topics: Adjuvants, Immunologic; Administration, Topical; Adult; Aminoquinolines; Child; Combined Modality Therapy; Cryotherapy; Female; Hand; Heel; Humans; Imiquimod; Interferon Inducers; Male; Salicylic Acid; Toes; Warts | 2002 |
Plantar wart treatment with combination imiquimod and salicylic acid pads.
Topics: Administration, Topical; Adult; Aminoquinolines; Drug Therapy, Combination; Foot; Humans; Imiquimod; Male; Salicylic Acid; Warts | 2003 |
Self-applied treatment of persistent plantar wart with 5% imiquimod cream.
Topics: Adjuvants, Immunologic; Adult; Aminoquinolines; Foot Diseases; Humans; Imiquimod; Keratolytic Agents; Male; Occlusive Dressings; Salicylic Acid; Warts | 2007 |
Lanolin-based organogel of salicylic acid: evidences of better dermatokinetic profile in imiquimod-induced keratolytic therapy in BALB/c mice model.
Topics: Administration, Topical; Aminoquinolines; Animals; Disease Models, Animal; Drug Carriers; Excipients; Gels; Imiquimod; Keratolytic Agents; Keratosis; Lanolin; Male; Mice, Inbred BALB C; Salicylic Acid; Skin; Skin Absorption | 2018 |
Local and distal involution of recalcitrant warts after a single intralesional dose of measles, mumps, and rubella vaccine.
Topics: Adjuvants, Immunologic; Bystander Effect; Child; Cryotherapy; Cytoreduction Surgical Procedures; Elbow; Hand Dermatoses; Humans; Imiquimod; Injections, Intralesional; Keratolytic Agents; Male; Measles-Mumps-Rubella Vaccine; Salicylic Acid; Treatment Failure; Warts | 2018 |
Effect of Metamorphed Keratolytic Agent on the Behavior of Imiquimod Loaded Hybrid Vesicles Containing Gel.
Topics: Administration, Topical; Animals; Dermatologic Agents; Drug Carriers; Drug Delivery Systems; Female; Gels; Imiquimod; Keratolytic Agents; Male; Mice; Particle Size; Permeability; Phospholipids; Rats; Rats, Sprague-Dawley; Salicylic Acid; Skin; Skin Absorption | 2019 |
5-Fluorouracil 0.5%/salicylic acid 10% solution in the treatment of ano-genital warts.
Topics: Adult; Condylomata Acuminata; Female; Fluorouracil; Humans; Imiquimod; Male; Pain; Salicylic Acid; Treatment Outcome; Warts | 2022 |
Imiquimod: a novel treatment for lentigo maligna.
Topics: Aged; Aged, 80 and over; Aminoquinolines; Antineoplastic Agents; Humans; Hutchinson's Melanotic Freckle; Imiquimod; Interferon Inducers; Male; Scalp; Skin Neoplasms | 2000 |
Infantile hemangioma: clinical resolution with 5% imiquimod cream.
Topics: Administration, Topical; Aminoquinolines; Antineoplastic Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Hemangioma, Capillary; Humans; Imiquimod; Male; Scalp; Skin Neoplasms | 2002 |
Topical imiquimod in the treatment of metastatic melanoma to skin.
Topics: Adjuvants, Immunologic; Administration, Cutaneous; Aged; Aged, 80 and over; Aminoquinolines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therapy; Dacarbazine; Female; Humans; Imiquimod; Interferon alpha-2; Interferon-alpha; Knee; Leg; Lymphatic Metastasis; Male; Melanoma; Middle Aged; Neoplasm Recurrence, Local; Nitrosourea Compounds; Organophosphorus Compounds; Recombinant Proteins; Scalp; Skin Neoplasms; Treatment Outcome | 2003 |
Infiltrative squamous cell carcinoma on the scalp after treatment with 5% imiquimod cream.
Topics: Adjuvants, Immunologic; Aged; Aged, 80 and over; Aminoquinolines; Carcinoma, Squamous Cell; Dosage Forms; Head and Neck Neoplasms; Humans; Imiquimod; Male; Scalp; Skin Neoplasms | 2005 |
A case of epidermodysplasia verruciformis associated with squamous cell carcinoma and Bowen's disease: a therapeutic challenge.
Topics: Administration, Cutaneous; Aminoquinolines; Antineoplastic Agents; Bowen's Disease; Carcinoma, Squamous Cell; Diagnosis, Differential; Drug Therapy, Combination; Epidermodysplasia Verruciformis; Humans; Imiquimod; Interferons; Male; Middle Aged; Scalp; Skin Neoplasms | 2006 |
Invasive squamous cell carcinoma after treatment of carcinoma in situ with 5% imiquimod cream.
Topics: Administration, Topical; Aged, 80 and over; Aminoquinolines; Antineoplastic Agents; Carcinoma in Situ; Carcinoma, Squamous Cell; Disease Progression; Head and Neck Neoplasms; Humans; Imiquimod; Leg; Lymph Node Excision; Lymphatic Metastasis; Male; Middle Aged; Neoplasms, Second Primary; Scalp; Skin Neoplasms; Treatment Outcome | 2006 |
Squamous cell carcinoma on the scalp following treatment with 5% imiquimod cream.
Topics: Administration, Topical; Aged, 80 and over; Aminoquinolines; Antineoplastic Agents; Carcinoma, Squamous Cell; Head and Neck Neoplasms; Humans; Imiquimod; Keratosis; Male; Radiodermatitis; Scalp; Skin Neoplasms | 2007 |
Residual basal cell carcinoma after treatment with imiquimod: a caution on assuming complete cure.
Topics: Administration, Topical; Aged, 80 and over; Aminoquinolines; Antineoplastic Agents; Carcinoma, Basal Cell; Female; Humans; Imiquimod; Neoplasm, Residual; Scalp; Skin Neoplasms; Treatment Failure | 2007 |
Complete remission of cutaneous and subcutaneous melanoma metastases of the scalp with imiquimod therapy.
Topics: Aminoquinolines; Antineoplastic Agents; Head and Neck Neoplasms; Humans; Imiquimod; Male; Melanoma; Middle Aged; Remission Induction; Scalp; Skin Neoplasms; Treatment Outcome | 2009 |
The use of imiquimod to minimize the surgical defect when excising invasive malignant melanoma surrounded by extensive melanoma in situ, lentiginous type.
Topics: Adjuvants, Immunologic; Aged, 80 and over; Aminoquinolines; Cheek; Female; Follow-Up Studies; Humans; Imiquimod; Male; Melanoma; Middle Aged; Neoplasm Invasiveness; Scalp; Skin Neoplasms; Wound Healing | 2009 |
Complete basal cell carcinoma remission with imiquimod in a patient with nevoid basal cell carcinoma syndrome and associated basal cell carcinoma of the scalp and invasive ductal breast cancer.
Topics: Aminoquinolines; Basal Cell Nevus Syndrome; Carcinoma, Basal Cell; Carcinoma, Ductal, Breast; Combined Modality Therapy; Female; Head and Neck Neoplasms; Humans; Imiquimod; Middle Aged; Patched Receptors; Receptors, Cell Surface; Scalp; Skin Neoplasms | 2011 |
Giant basal cell carcinoma. Improvement and vitiligo-like hypopigmentation after intermittent treatment with 5% imiquimod.
Topics: Aged; Aminoquinolines; Antineoplastic Agents; Carcinoma, Basal Cell; Female; Head and Neck Neoplasms; Humans; Imiquimod; Scalp; Skin Neoplasms; Vitiligo | 2012 |
Lichen planopilaris after imiquimod 5% cream for multiple BCC in basal cell naevus syndrome.
Topics: Alopecia; Aminoquinolines; Antineoplastic Agents; Basal Cell Nevus Syndrome; Drug Eruptions; Female; Head and Neck Neoplasms; Humans; Imiquimod; Lichen Planus; Middle Aged; Scalp; Skin Cream; Skin Neoplasms | 2015 |
Clinical experience of imiquimod 3.75% for actinic keratosis: results from a case series.
Topics: Adjuvants, Immunologic; Aged; Aged, 80 and over; Aminoquinolines; Cohort Studies; Dermatologic Agents; Face; Female; Follow-Up Studies; Humans; Imiquimod; Keratosis, Actinic; Male; Middle Aged; Scalp; Treatment Outcome | 2018 |
Efficacy and Safety of Imiquimod 3.75% from Lmax in Actinic Keratosis According to Fitzpatrick Skin Type.
Topics: Adjuvants, Immunologic; Administration, Topical; Aged; Aminoquinolines; Double-Blind Method; Face; Female; Humans; Imiquimod; Keratosis, Actinic; Male; Middle Aged; Randomized Controlled Trials as Topic; Scalp; Treatment Outcome | 2016 |
Clinical and histological resolution of invasive squamous cell carcinoma by topical imiquimod 3.75%: a case report.
Topics: Administration, Cutaneous; Aged; Aminoquinolines; Antineoplastic Agents; Carcinoma, Squamous Cell; Head and Neck Neoplasms; Humans; Imiquimod; Male; Neoplasm Invasiveness; Scalp; Skin Neoplasms | 2016 |
Topical imiquimod clears invasive melanoma.
Topics: Administration, Cutaneous; Aged; Aminoquinolines; Antineoplastic Agents; Head and Neck Neoplasms; Humans; Imiquimod; Male; Melanoma; Scalp; Skin Neoplasms | 2016 |
Successful treatment of multifocal pigmented basal cell carcinomas with the application of topical 5% imiquimod cream.
Topics: Administration, Cutaneous; Aged; Antineoplastic Agents; Carcinoma, Basal Cell; Head and Neck Neoplasms; Humans; Imiquimod; Male; Neoplasms, Multiple Primary; Scalp; Skin Cream; Skin Neoplasms | 2018 |
Two cases of erosive pustular dermatosis of the scalp occurring after topical 3.75% imiquimod for actinic keratoses.
Topics: Administration, Cutaneous; Aged; Aged, 80 and over; Clobetasol; Dermatologic Agents; Drug Eruptions; Humans; Imiquimod; Keratosis, Actinic; Male; Scalp; Scalp Dermatoses; Treatment Outcome | 2019 |
Efficacy of topical imiquimod 3.75% in the treatment of actinic keratosis of the scalp in immunosuppressed patients: our case series.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Erythema; Female; Humans; Imiquimod; Immunocompromised Host; Keratosis, Actinic; Male; Middle Aged; Scalp; Treatment Outcome | 2020 |